A cost analysis of MR-guided laser interstitial thermal therapy for adult refractory epilepsy

Epilepsia. 2023 Sep;64(9):2286-2296. doi: 10.1111/epi.17693. Epub 2023 Jul 10.

Abstract

Objective: MR-guided laser interstitial thermal therapy (LITT) is used increasingly for refractory epilepsy. The goal of this investigation is to directly compare cost and short-term adverse outcomes for adult refractory epilepsy treated with temporal lobectomy and LITT, as well as to identify risk factors for increased costs and adverse outcomes.

Methods: The National Inpatient Sample (NIS) was queried for patients who received LITT between 2012 and 2019. Patients with adult refractory epilepsy were identified. Multivariable mixed-effects models were used to analyze predictors of cost, length of stay (LOS), and complications.

Results: LITT was associated with reduced LOS and overall cost relative to temporal lobectomy, with a statistical trend toward lower incidence of postoperative complications. High-volume surgical epilepsy centers had lower LOS overall. Longer LOS was a significant driver of increased cost for LITT, and higher comorbidity was associated with non-routine discharge.

Significance: LITT is an affordable alternative to temporal lobectomy for adult refractory epilepsy with an insignificant reduction in inpatient complications. Patients may benefit from expanded access to this treatment modality for both its reduced LOS and lower cost.

Keywords: cerebral edema; cost; epilepsy; intracranial hemorrhage; laser interstitial thermal therapy (LITT); seizure; stereotactic laser ablation.

MeSH terms

  • Adult
  • Costs and Cost Analysis
  • Drug Resistant Epilepsy* / etiology
  • Drug Resistant Epilepsy* / surgery
  • Humans
  • Laser Therapy* / adverse effects
  • Lasers
  • Magnetic Resonance Imaging
  • Treatment Outcome